光动力疗法治疗肝外胆管癌的疗效分析
本研究为回顾性队列研究,纳入86例肝外胆管癌患者,比较光动力疗法(PDT)联合胆道支架置入与单纯支架置入的疗效。经倾向性评分匹配后,PDT组与支架组术后总体并发症发生率均为18.2%(4/22),差异无统计学意义(P>0.05);PDT组中位总生存时间17.8个月,支架组6.4个月,差异有统计学意义(P=0.011)。结论认为PDT联合支架可有效延长生存时间且不增加并发症风险。
要点
- PDT联合胆道支架可延长肝外胆管癌患者中位总生存时间(17.8个月 vs 6.4个月,P=0.011)。
- PDT不增加术后总体并发症发生率(均为18.2%,P>0.05)。
- 经PTC或ERCP途径实施PDT的并发症与生存差异均无统计学意义。
核心结论
- PDT联合胆道支架置入可有效延长肝外胆管癌患者总体生存时间,且不增加术后并发症风险。
- 经PTC与ERCP途径实施PDT对治疗效果及安全性无显著影响。
研究设计与样本
- 回顾性队列研究,纳入2021年6月至2025年6月西安交通大学第一附属医院86例肝外胆管癌患者。
- 男性59例,女性27例,年龄(70.2±9.0)岁(范围37~91岁)。
- 按治疗方案分为PDT组(39例)和胆道支架置入组(47例),采用1∶1最近邻倾向性评分匹配(容差0.1)。
- PDT组进一步分为经皮经肝胆管穿刺造影(PTC)亚组和经内镜逆行胰胆管造影(ERCP)亚组。
主要发现
- 经PSM后22对患者匹配,PDT组与支架组术后总体并发症发生率均为18.2%(4/22),差异无统计学意义(P>0.05)。
- 各类具体并发症发生率组间差异均无统计学意义(P值均>0.05)。
- PDT组与支架组中位总生存时间分别为17.8个月和6.4个月,差异有统计学意义(P=0.011)。
- 经PTC与ERCP途径行PDT患者术后并发症发生率分别为18.5%(5/27)和2/12,中位生存时间分别为17.8个月和未获得,差异均无统计学意义(P值均>0.05)。
临床怎么用
- 对于肝外胆管癌患者,可考虑PDT联合胆道支架置入以延长生存时间。
- PDT实施途径(PTC或ERCP)可根据临床条件选择,疗效与安全性无显著差异。
局限性
- 本研究为单中心回顾性队列研究,样本量有限(86例),结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the safety and efficacy of photodynamic therapy(PDT) combined with biliary stent implantation in the treatment of extrahepatic cholangiocarcinoma. Methods: A retrospective cohort analysis was conducted based on the clinical and imaging data of patients with extrahepatic cholangiocarcinoma admitted to the First Affiliated Hospital of Xi'an Jiaotong University from June 2021 to June 2025. Eighty-six patients were enrolled in this study, there were 59 males and 27 females, with an age of (70.2±9.0) years (range: 37 to 91 years). Patients were divided into two groups according to the treatment regimen: the PDT combined with biliary stent implantation group (39 cases) and the biliary stent implantation group (47 cases). A 1∶1 nearest-neighbor propensity score matching (PSM) was performed with a caliper width of 0.1. Furthermore, patients in the PDT group were subclassified into the percutaneous transhepatic cholangiography (PTC) subgroup and the endoscopic retrograde cholangiopancreatography (ERCP) subgroup based on the intervention approach. The postoperative complication rate and postoperative overall survival time were compared by independent samples t-test, Mann-Whitney U test, χ2 test or Fisher's exact test between the two groups. Survival analysis was conducted using the Kaplan-Meier method, and the Log-rank test was applied for intergroup comparisons. Results: After PSM matching,the overall incidence of postoperative complications was 18.2% (4/22) in both the PDT group and the stenting group, with no statistically significant difference (P>0.05). No significant differences were observed in the incidence of each specific complications between the two groups (all P>0.05). Survival analysis showed that the median overall survival (mOS) time of the PDT combined with stent group and the stent group were 17.8 months and 6.4 months,respectively,with a statistically significant difference (P=0.011). For PDT patients undergoing the PTC versus ERCP approach, the incidence of postoperative complications was 18.5% (5/27) and 2/12, respectively; the mOS time was 17.8 months versus not reached, with no statistically significant difference (all P>0.05). Conclusions: PDT combined with biliary stent implantation can effectively prolong the overall survival time of patients with extrahepatic cholangiocarcinoma without increasing the risk of postoperative complications. Additionally,the administration of PDT via the PTC and ERCP approaches has no significant impact on the therapeutic efficacy and safety. 目的: 探讨光动力疗法(PDT)治疗肝外胆管癌的可行性和有效性。 方法: 本研究为回顾性队列研究。回顾性分析2021年6月至2025年6月于西安交通大学第一附属医院接受诊治的86例肝外胆管癌患者的临床和影像学资料。男性59例,女性27例,年龄(70.2±9.0)岁(范围:37~91 岁)。根据治疗方案不同将患者分为两组:PDT组(39例)和胆道支架置入术组(支架组)(47例)。采用倾向性评分匹配(PSM)法进行1∶1最近邻匹配,容差为0.1。进一步根据操作途径将PDT患者分为经皮经肝胆管穿刺造影(PTC)组和经内镜逆行胰胆管造影(ERCP)组。采用独立样本t检验、Mann-Whitney U检验、χ2检验或Fisher确切概率法比较组间患者的术后并发症发生率及术后总体生存时间。采用Kaplan-Meier曲线进行生存分析,并通过Log-rank 法进行比较。 结果: 经PSM后,共22对患者成功匹配。PDT组与支架组术后总体并发症发生率均为18.2%(4/22),差异无统计学意义(P>0.05)。各类具体并发症发生率的差异亦无统计学意义(P值均>0.05)。生存分析结果显示,PDT组与支架组的中位生存时间分别为17.8个月和6.4个月,差异有统计学意义(P=0.011)。经PTC与ERCP途径行PDT治疗患者的术后并发症发生率分别为18.5%(5/27)和2/12,中位生存时间分别为17.8个月和未获得,差异均无统计学意义(P值均>0.05)。 结论: PDT在不增加肝外胆管癌患者术后并发症风险的前提下,可有效延长患者的总体生存时间,经PTC与ERCP途径实施PDT对治疗效果及并发症无显著差异。.
引用
- Chen C, Liu HC, Wang RF, et al. [Efficacy of photodynamic therapy in extrahepatic cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41771526. doi:10.3760/cma.j.cn112139-20251104-00519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。